<DOC>
	<DOCNO>NCT02832544</DOCNO>
	<brief_summary>This program comprehensive evaluation rheumatic valvular heart disease ( RVHD ) , Atrial fibrillation ( AF ) /flutter stroke . A prospective , randomize , parallel group , open-label clinical trial rivaroxaban versus standard vitamin K antagonist ( VKA ) therapy evaluate non-inferiority rivaroxaban VKA , test superiority non-inferiority satisfy .</brief_summary>
	<brief_title>INVestIgation rheumatiC AF Treatment Using Vitamin K Antagonists , Rivaroxaban Aspirin Studies , Non-Inferiority</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Rheumatic Diseases</mesh_term>
	<mesh_term>Rheumatic Heart Disease</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>1 . RVHD diagnose echocardiography time prior enrollment 2 . Age ≥18 3 . Increased risk stroke follow CHA2DS2VASc score ≥ 2 OR Moderate/Severe mitral stenosis valve area ≤2.0 cm2 OR Left atrial spontaneous echo contrast OR Left atrial thrombus 4 . Heart Rhythm *AF Flutter document baseline 12lead ECG , previous 12lead ECG , Holter monitor , inhospital ECG rhythm strip Pacemaker ICD electrogram . 1 . Refusal give inform consent 2 . Actively involved study would compromise protocol INVICTUS Trial 3 . Severe comorbid condition life expectancy &lt; 1 year 4 . Other serious condition ( ) logistic factor likely interfere study participation ability complete trial , appropriate country region . 5 . Likely valve replacement surgery within 6 month 6 . Mechanical valve prosthesis condition require treatment VKAs . Patients deep vein thrombosis recent pulmonary embolism enrol VKAs rivaroxaban approve . 7 . Contraindication study medication trial Allergy rivaroxaban Allergy VKAs ( noninferiority trial ) Allergy aspirin ( superiority trial ) 8 . Severe renal insufficiency calculate creatinine clearance ( CockcroftGault ) &lt; 15 ml/min 9 . Serious bleed past six month high risk bleed 10 . Moderate severe hepatic impairment 11 . Ongoing need dual antiplatelet therapy ( patient ongoing aspirin therapy ≤100 mg per day exclude ) 12 . Ongoing need dual strong inhibitor CYP3a4 pglycoprotein inhibitor . 13 . Received investigational drug past 30 day 14 . Patients consider unsuitable trial inclusion unwillingness attend follow visit 15 . Women pregnant and/or breastfeed 16 . Women child bear age use effective form birth control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>atrial fibrillation</keyword>
	<keyword>stroke</keyword>
</DOC>